|
|
Article: MIV Therapeutics to Highlight Latest HAp Advancements at Leading International Scientific Conference on Biomaterials; MIVT Accepted to Present Proprietary Biocompatible Stent Coating Technology at Society of Biomaterials Meeting.
- Article from:
- Business Wire
- Article date:
- January 31, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced today that it has been accepted to present some of its latest technology achievements at the annual international meeting of the Society of Biomaterials in Pittsburgh, Pennsylvania, in April.
MIV Therapeutics is a leader in the research and development of a novel organic material, called Hydroxyapatite (HAp), which is designed to provide medically needed advantages over the current generation of polymer coatings and ...